Rating

B+

Review of Knight Therapeutics

AUG 27, 2020 - After a lengthy waiting period for investors, GUD finally closed a large deal in the last quarter of 2019, albeit in a non-traditional way. For patient investors, the potential growth remains while holding a company that provides stability through a large cash position. Rating maintained at ‘B+’.

Download Report

• Knight Therapeutics Inc. (GUD)
  • View GUD Profile
  • View Questions on GUD
  • View Reports on GUD

Add to favourite

Q: Thoughts on the quarter?

Read Answer Asked by Chris on May 14, 2021

• Knight Therapeutics Inc. (GUD)
  • View GUD Profile
  • View Questions on GUD
  • View Reports on GUD

Add to favourite

Q: Thoughts on the leadership change? Would you consider this material news that will impact the shares (positively or negatively)?

Read Answer Asked by Mike on May 13, 2021

• Knight Therapeutics Inc. (GUD)
  • View GUD Profile
  • View Questions on GUD
  • View Reports on GUD

Add to favourite

Q: Good morning team,
Any idea why GUD has halted?
Thx!

Read Answer Asked by Silvia on May 13, 2021